Thrombotic thrombocytopenic purpura in pregnancy. Giving birth or not giving birth, that is the question

Introduction. Pregnancy is one of the most frequent triggers of congenital and acquired forms of thrombotic thrombocytopenic purpura (TTP).

Aim — to develop tactics for the treatment of pregnant women with TTP.

Results. TTP was associated with pregnancy in 55.5 % of all cases of TTP in women. In 5 pregnancies in which the diagnosis of TTP was known before pregnancy, or established in the early stages, TTP was treated throughout the pregnancy. In the congenital form, plasma transfusions were performed once every two weeks until the  20th  week of pregnancy, or  weekly, if thrombocytopenia < 150 × 10⁹ /L persisted. Plasma transfusions were performed weekly after the 20th week with the goal of achieving clinical remission. With acquired TTP, glucocorticosteroids and plasma exchanges were used as  treatment, in 1 case — rituximab, with the aim of achieving a clinical remission and an ADAMTS13 activity > 20 %. In this group of pregnant women, 1 caesarean section was performed and there were 4 cases of vaginal deliveries, with a total of 5 children being born with an average Apgar score of 7.5. In 7 pregnancies in which TTP fi rst manifested late, leading to a delayed diagnosis, preventive and curative measures were not carried out before delivery. In this group there were 2 abortions of pregnancy, 5 surgical deliveries, 3 cases of preeclampsia, 3 acute cerebral circulatory disorders, 1 intraabdominal bleeding, 1 case of acute renal failure, with two women undergoing mechanical ventilation. There was 1 case of antenatal fetal death, with a total of 4 children being born, who were assessed on the Apgar scale with an average of 5 points.

Conclusion. Timely diagnosis as well as ongoing therapeutic and preventive measures help to avoid complications during childbirth in pregnant women with TTP.

1. Scully M., Cataland S., Coppo P., et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017; 15(2): 312–22. DOI: 10.1111/jth.13571.

2. Roose E., Tersteeg C., Demeersseman R., et al. Anti-ADAMTS13 antibodies and a novel heterozygous p.R1177Q mutation in a case of pregnancy-onset immunemediated thrombotic thrombocytopenic purpura. TH Open. 2018; 02(01): e8–15. DOI: 10.1055/s-0037-1615252.

3. Mariotte E., Azoulay E., Galicier L., et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 defi -ciency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French National Registry for thrombotic microangiopathy. Lancet Haematol. 2016; 3(5): e237–45. DOI: 10.1016/S2352-3026(16)30018-7.

4. Mancini I., Pontiggia S., Palla R., et al. Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: Fourteen years of the Milan TTP Registry. Thromb Haemost. 2019; 119(5): 695–704. DOI: 10.1055/s-0039-1679907.

5. Huang F., Li X.P., Xu Y., et al. Clinical characteristics and outcomes of adult patients with acquired thrombotic thrombocytopenic purpura: A single center retrospective study. Ann Palliat Med. 2021; 10(5): 5351–8. DOI: 10.21037/apm-21-759.

6. Vesely S.K. Life after acquired thrombotic thrombocytopenic purpura: Morbidity, mortality, and risks during pregnancy. J Thromb Haemost. 2015; 13(S1): S216–22. DOI: 10.1111/jth.12953.

7. Rottenstreich A., Dor S., Keren-Politansky A., et al. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age. J Thromb Thrombolysis. 2021; 51(1): 187–93. DOI: 10.1007/s11239-020-02133-4.

8. Delmas Y., Helou S., Chabanier P., et al. Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women: A diffi cult diagnosis and a treatable disease. BMC Pregnancy Childbirth. 2015; 15(1): 1–8. DOI: 10.1186/s12884-015-0557-5.

9. Sánchez-Luceros A., Farías C.E., Amaral M.M., et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost. 2004; 92(6): 1320–6. DOI: 10.1160/TH03-11-0683.

10. Моmot A.P., Моlchanova I.V., Batrak Т.А., et al. Reference values of hemostatic system parameters in normal pregnancy and after delivery. Problemi Reproductsii. 2015; 21(1): 89–97. DOI: 10.17116/repro20152189-97. (In Russian).

11. Adamidou D., Rouka E., Verrou E., et al. Association of ADAMTS13 activity with gender in normal adult cohort. Blood. 2008; 112(11): 4554. DOI: 10.1182/blood.V112.11.4554.4554 .

12. Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci. 2016; 54(2): 199–202. DOI: 10.1016/j.transci.2016.04.009.

13. Ferrari B., Maino A., Lotta L.A., et al. Pregnancy complications in acquired thrombotic thrombocytopenic purpura: A case-control study. Orph J Rare Dis. 2014; 9: 193. DOI: 10.1186/s13023-014-0193-6.

14. Jiang Y., McIntosh J.J., Reese J.A., et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014; 123(11): 1674–80. DOI: 10.1182/blood-2013-11-538900.

15. Gupta M., Feinberg B.B., Burwick R.M. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens. 2018; 12: 29–34. DOI: 10.1016/j.preghy.2018.02.007.

16. Al-Husban N., Al-Kuran O. Post-partum thrombotic thrombocytopenic purpura (TTP) in a patient with known idiopathic (immune) thrombocytopenic purpura: A case report and review of the literature. J Med Case Rep. 2018; 12(1): 147. DOI: 10.1186/s13256-018-1692-1.

17. Soe A.M., Tun N.M., Guevara E., Shulimovich M. A case of thrombotic thrombocytopenic purpura in late pregnancy. Blood Res. 2016; 51(3): 207–14. DOI: 10.5045/br.2016.51.3.207.

18. Nikolaou M., Karakantza M., Adonakis G., et al. A case of severe ADAMTS13 defi ciency presenting as thrombotic thrombocytopenic purpura in pregnancy. Med Pregl. 2012; 65(9–10): 436–9. DOI: 10.2298/MPNS1210436N.

19. Fyfe-Brown A., Clarke G., Nerenberg K., et al. Management of pregnancyassociated thrombotic thrombocytopenia purpura. Am J Perinatol Rep. 2012; 3(1): 45–50. DOI: 10.1055/s-0032-1331380.

20. Panaitescu A.M., Stoia R., Ciobanu A.M., et al. Pregnancy shortly after an acute episode of severe acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2016; 55(3): 308–10. DOI: 10.1016/j.transci.2016.08.002.

21. Nonaka T., Yamaguchi M., Nishijima K., et al. A successfully treated case of an acute presentation of congenital thrombotic thrombocytopenic purpura (Upshaw – Schulman syndrome) with decreased ADAMTS13 during late stage of pregnancy. J Obs Gynaecol Res. 2021; 47(5): 1892–7. DOI: 10.1111/jog.14737.

22. Kasht R., Borogovac A., George J.N. Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura. Ame J Hematol. 2020; 95(11): E316–8. DOI: 10.1002/ajh.25964.

23. Savignano C., Rinaldi C., De Angelis V. Pregnancy associated thrombotic thrombocytopenic purpura: Practical issues for patient management. Transfus Apher Sci. 2015; 53(3): 262–8. DOI: 10.1016/j.transci.2015.11.005.

24. Scully M., Thomas M., Underwood M., et al. Thrombotic thrombocytopenic purpura and pregnancy: Presentation, management, and subsequent pregnancy outcomes. Blood. 2014; 124(2): 211–9. DOI: 10.1182/blood-2014-02-553131.

25. Voitsekhovskii V.V., Filatov L.B., Pivnik A.V. Diagnosis and treatment of thrombotic thrombocytopenic purpura developed during gestation: Literature review and case report. Klinicheskaya onkogematologiya. 2014; 7(4): 587–98. (In Russian).

26. Mancini I. ADAMTS13-related assays in acquired thrombotic thrombocytopenic purpura. Università degli studi di Milano; 2012.

27. Vendramin C., Thomas M., Westwood J.-P., Scully M. Bethesda assay for detecting inhibitory anti-ADAMTS13 antibodies in immune-mediated thrombotic thrombocytopenic purpura. TH Open. 2018; 2(3): e329–33. DOI: 10.1055/s0038-1672187.

28. Shelat S.G., Smith P., Ai I., Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006; 4(8): 1707–17. DOI: 10.1111/j.1538-7836.2006.02025.x.

29. Galstyan G.M, Spirin M.V. Vascular access in hematology. Moscow: Praktika Publ.; 2021. (In Russian).

30. Melikyan A.L., Pustovaya E.I., Tsvetaeva N.V., et al. Clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofi brosis) (edition 2016). Gematologiya I Transfusiologiya. 2017; 62(1-S1): 25–60. DOI: 10.18821/0234-5730-2017-62-1-S1-1-60. (In Russian).

31. Grall M., Azoulay E., Galicier L., et al. Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. Am J Hematol. 2017; 92(4): 381–7. DOI: 10.1002/ajh.24665.

32. Moatti-Cohen M., Garrec C., Wolf M., et al. Unexpected frequency of Upshaw – Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012; 119(24): 5888–97. DOI: 10.1182/blood-2012-02-408914.

33. Zheng X. Structure-function and regulation of ADAMTS13. J Thromb Haemost. 2013; 11(Suppl 1): 11–23. DOI: 10.1111/jth.12221.

34. Gangaraju R., Rodgers G.M. Upshaw – Schulman syndrome and pregnancy: Successful management with plasma infusions. Ann Hematol. 2016; 95(10): 1745–6. DOI: 10.1007/s00277-016-2755-2.

35. Sakai K., Fujimura Y., Nagata Y., et al. Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18(11): 2929–41. DOI: 10.1111/jth.15064.

36. Miodownik S., Pikovsky O., Erez O., et al. Unfolding the pathophysiology of congenital thrombotic thrombocytopenic purpura in pregnancy: Lessons from a cluster of familial cases. Am J Obs Gynecol. 2021; 225(2): 177.e1–15. DOI: 10.1016/j.ajog.2021.02.018.

37. Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011; 7(1): 28–31. DOI: 10.4161/ORG.7.1.14027.

38. Picod A., Coppo P. When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP. Transfus Apher Sci. 2019; 58(3): 273–7. DOI: 10.1016/J.TRANSCI.2019.04.012.

39. Fomin A.M., Zatsepina A.A., Golenkov A.K., et al. The plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Gematologiya I Transfusiologiya. 2017; 62(2): 96–100. DOI: 10.18821/0234-5730/2017-62-2-96-100. (In Russian).

40. Scully M., Starke R., Lee R., et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinol. 2006; 17(6): 459–63. DOI: 10.1097/01.mbc.0000240918.65306.20 .

41. Vesely S.K., Li X., McMinn J.R., et al. Transfusion practice. Transfusion. 2004; 44(8): 1149–58. DOI: 10.1111/j.1537-2995.2004.03422.x.

42. Scully M., Hunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158(3): 323–35. DOI: 10.1111/j.1365-2141.2012.09167.x.

43. Benhamou Y., Baudel J.L., Wynckel A., et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. Am J Hematol. 2015; 90(6): E127–9. DOI: 10.1002/ajh.23997.

44. Vinet E., Pineau C., Gordon C., et al. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum. 2009; 61(5): 587–92. DOI: 10.1002/art.24462.

45. Smith J.B., Hellwig K., Fink K., et al. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinfl am. 2020; 7(4): e734. DOI: 10.1212/NXI.0000000000000734.

46. Harris C., Marin J., Beaulieu M.C. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: A case report. BMC Nephrol. 2018; 19(1): 4–7. DOI: 10.1186/s12882-018-0949-7.

47. Simister N.E. Placental transport of immunoglobulin G. Vaccine. 2003; 21(24): 3365–9. DOI: 10.1016/s0264-410x(03)00334-7.

48. Saji F., Samejima Y., Kamiura S., Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999; 4(2): 81–9. DOI: 10.1530/ror.0.0040081.

49. Ton E., Tekstra J., Hellmann P.M., et al. Safety of rituximab therapy during twins’ pregnancy. Rheumatology (Oxford). 2011; 50(4): 806–8. DOI: 10.1093/rheumatology/keq403.

50. Das G., Damotte V., Gelfand J.M., et al. Rituximab before and during pregnancy. Neurol Neuroimmunol Neuroinfl amm. 2018; 5(3): e453. DOI: 10.1212/nxi.0000000000000453.